), Halozyme Therapeutics has received 394 “underperform” votes. The P/E ratio of Halozyme Therapeutics is 300.56, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 42.43. View HALO's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. High institutional ownership can be a signal of strong market trust in this company. Halozyme Therapeutics has a market capitalization of $6.50 billion and generates $195.99 million in revenue each year. How to Supercharge Your Ability to Learn Any New Subject, Stocks open lower on Wall Street, Treasury yields climb, Closing prices for crude oil, gold and other commodities, Texas crisis has governor facing big backer: energy industry, Perion Networks Stock Has More Upside From Here, Coty Stock Providing Pullback Opportunities, America’s Car-Mart (NASDAQ:CRMT) Sets New High As Business Accelerates, 6 Hot Cannabis Stocks For Penny Stock Investors, Bloomin' Brands Edges Out Expectations, Looks Forward to Future, 3 S&P 500 Laggards in 2020 Turned Leaders in 2021, Echo Park Drives Growth For Sonic Automotive Stock, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, 7 Electric Vehicle (EV) Stocks That Have Real Juice, 7 Post-Inauguration Stocks to Buy For Under $20, 7 Cryptocurrencies That Are Leading The Market Higher, 7 Stocks to Support Your New Year’s Resolutions, 7 Things You Need To Know About Cryptocurrency, Halozyme To Host Fourth Quarter And Full Year 2020 Financial Results Webcast And Conference Call, Antidiabetics Market (Impact of COVID-19) Size, Status and Forecast 2020-2025, Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO® (Daratumumab And Hyaluronidase-fihj) As Treatment For Newly Diagnosed Patients With Light Chain (AL) Amyloidosis, First Week of September 17th Options Trading For Halozyme Therapeutics (HALO), Regeneron (REGN), U.S. Government Ink Deal for COVID-19 Treatment, Sarepta (SRPT) Looks Good: Stock Adds 9.1% in Session, Halozyme Provides 2021 Financial Guidance Highlighted By Strong Revenue And EPS Growth, Halozyme To Present Virtually At The 39th Annual J.P. Morgan Healthcare Conference, A Technical Update on Halozyme Therapeutics, Breast Cancer Therapeutics Drugs Market 2021 Growth After Covid-19 Pandemic with Top Manufacturers: Bayer HealthCare, Eli Lily, Pfizer. E26 Series 6 in. The HALO 10P is a white, square recessed lighting trim complete with a frosted glass Albalite lens. Interested parties can register for or listen to the call using this link or dial in at Not Available. Halo rings or corona rings are LED powered, ultra-bright rings found in many aftermarket conversion kits and headlight upgrades. The polymer trim ring is non-conductive and non-corrosive for use in wet locations. DOW 31,522.75. Halozyme Therapeutics employs 132 workers across the globe. You can opt out at any time. The company provided EPS guidance of 1.40-1.55 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.79. Sign-up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Free Shipping On Orders $45+. The post also says that there is âquite a bitâ of new content coming on the horizon and that the ⦠SHOP NOW: Nora Kogan, $815 20 of 87. Learn everything you need to know about successful options trading with this three-part video course. See what's happening in the market right now with MarketBeat's real-time news feed. © American Consumer News, LLC dba MarketBeat® 2010-2021. And you know what that means -- no changing bras when it's ⦠Only 2.60% of the stock of Halozyme Therapeutics is held by insiders. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; and National Institute of Allergy and Infectious Diseases. HALO stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Price T Rowe Associates Inc. MD, GW&K Investment Management LLC, Bank of New York Mellon Corp, Stephens Investment Management Group LLC, Principal Financial Group Inc., Northern Trust Corp, and Assenagon Asset Management S.A.. View insider buying and selling activity for Halozyme Therapeutics or or view top insider-buying stocks. 98.45% of the stock of Halozyme Therapeutics is held by institutions. Nobody expects what they're predicting now... Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, and internationally. The biopharmaceutical company reported $0.25 earnings per share for the quarter, topping analysts' consensus estimates of $0.20 by $0.05. View which stocks are hot on social media with MarketBeat's trending stocks report. Helen Torley has an approval rating of 75% among Halozyme Therapeutics' employees. Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345.
Thermador Dishwasher Keeps Running,
Orochi Opm Height,
Generalized Extreme Value Distribution - Matlab,
Alibaba Akpobome First Wife,
Adopt Me Dog,
Go Math Grade 7 Accelerated Answer Key Pdf,
Store Fixtures Philadelphia,
The Stinkier The Fart The Healthier You Are,
Throttle Position Sensor Relearn Procedure,
Mbalenhle Name Meaning,